Mary Claire Haver on Visceral Fat Explained

Mary Claire Haver's work on visceral fat has resonated with many midlife women seeking to understand why their body composition changes during perimenopause and menopause. Dr Haver, a US-based obstetrician and gynaecologist, argues that declining oestrogen drives fat redistribution towards the abdomen, raising cardiovascular and metabolic risk beyond what the scales alone reveal. This article explains what visceral fat is, why it matters, what Dr Haver recommends, what the clinical evidence supports, and when to speak to a UK GP about your own metabolic health.

Who is Dr Mary Claire Haver and why does she talk about visceral fat?

Dr Mary Claire Haver is a US board-certified obstetrician and gynaecologist who focuses on visceral fat because oestrogen decline during menopause drives abdominal fat redistribution, raising cardiometabolic risk. Her recommendations are educational and not a substitute for advice from a UK-registered clinician.

Dr Mary Claire Haver is a US-based board-certified obstetrician and gynaecologist who has become widely recognised for her work on menopause, metabolic health, and body composition in midlife women. She is the author of 'The Galveston Diet' and 'The New Menopause', and has built a substantial following on social media by translating clinical research on hormonal change and fat distribution into accessible, practical guidance. Her focus on visceral fat stems directly from her clinical observation that many perimenopausal and postmenopausal women experience significant shifts in where their body stores fat, even without major changes in overall weight.

Dr Haver argues that conventional medical consultations often underserve women in midlife by focusing on weight as a single number rather than addressing body composition, metabolic risk, and the hormonal drivers of fat redistribution. She draws on published research linking oestrogen decline to increased visceral adiposity, a relationship supported by peer-reviewed literature and referenced in British Menopause Society (BMS) resources on cardiometabolic risk in menopause. She uses her platform to highlight that this shift carries real cardiovascular and metabolic consequences.

It is important to note that Dr Haver's recommendations are educational in nature, reflect her interpretation of the available evidence, and are produced for a US audience. They are not a substitute for personalised medical advice from a UK-registered clinician. UK guidance from NICE (including NG23 on menopause) and NHS sources should always be the primary reference point for patients seeking clinical recommendations, and any significant concerns about metabolic health or body composition should be discussed with a GP.

What is visceral fat and why is it more dangerous than other body fat?

Visceral fat is stored deep within the abdominal cavity and is metabolically active, releasing inflammatory cytokines that drive insulin resistance, dyslipidaemia, and increased risk of type 2 diabetes and cardiovascular disease. NHS guidance uses waist circumference as a practical proxy measure for central adiposity.

Visceral fat is the fat stored deep within the abdominal cavity, surrounding internal organs such as the liver, pancreas, and intestines, and it carries a greater metabolic risk than subcutaneous fat, which sits just beneath the skin. Unlike subcutaneous fat, which is relatively inert, visceral fat is metabolically active. It releases fatty acids, inflammatory cytokines, and hormones directly into the portal circulation, which drains into the liver, contributing to insulin resistance, dyslipidaemia, and systemic inflammation.^[8][9]

This metabolic activity is why visceral fat accumulation is associated with an increased risk of type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease, even in individuals whose overall body mass index (BMI) falls within a normal range.^[8][9] Visceral adiposity has also been associated with higher risk of certain cancers, including colorectal cancer and postmenopausal breast cancer, though the strength of evidence varies by cancer type.

NHS guidance acknowledges that waist circumference is a useful proxy measure for central adiposity. For women, a waist measurement of 80 cm (31.5 inches) or above is associated with increased health risk, and 88 cm (35 inches) or above is associated with very high health risk. Different thresholds apply for men, and lower cut-offs are recommended for people of South Asian, Chinese, Japanese, and some other ethnic backgrounds, reflecting higher cardiometabolic risk at a given waist size.^[13] If you are unsure which threshold applies to you, your GP can advise.

During the perimenopause and menopause, declining oestrogen levels are associated with a shift in fat distribution from the hips and thighs towards the abdomen. Research published in peer-reviewed journals, including work cited in BMS and menopause society guidelines, supports the view that this redistribution is hormonally driven rather than solely a consequence of ageing or lifestyle. This is a key reason why Dr Haver and other clinicians working in women's health have drawn particular attention to visceral fat as a priority concern for midlife women, rather than focusing exclusively on total body weight.

What does Dr Haver recommend for reducing visceral fat in midlife women?

Dr Haver recommends an anti-inflammatory Mediterranean-style diet, resistance training, adequate protein intake, sleep optimisation, and stress management to reduce visceral fat in midlife women. She also discusses HRT as potentially attenuating menopause-related central fat redistribution, though it is not licensed for this purpose.

Dr Haver recommends a combination of dietary changes, resistance training, adequate protein intake, sleep optimisation, and stress management as the core strategies for reducing visceral fat in midlife women. Her approach, outlined in her published books and public communications, emphasises an anti-inflammatory dietary pattern broadly consistent with a Mediterranean-style diet: prioritising whole foods, vegetables, legumes, oily fish, and healthy fats; limiting ultra-processed foods and added sugars; and ensuring sufficient dietary protein to support muscle mass preservation during hormonal transition.

She places particular emphasis on resistance exercise, arguing that building and maintaining skeletal muscle is critical for metabolic health in postmenopausal women, as muscle tissue improves insulin sensitivity and supports a healthier body composition over time. She also discusses the role of sleep quality and cortisol management, noting that chronic sleep disruption and elevated stress hormones can independently promote visceral fat accumulation.

Dr Haver also discusses hormone replacement therapy (HRT, also referred to as menopausal hormone therapy or MHT in some international literature) in the context of body composition, citing evidence suggesting that oestrogen therapy may attenuate the menopause-related shift towards central adiposity.^[18][16] In the UK, HRT is available on the NHS and NICE guideline NG23 on menopause supports its use for managing menopausal symptoms where appropriate, following an individualised risk-benefit discussion with a clinician. HRT is not licensed specifically as a treatment for visceral fat reduction, and it should not be initiated solely for the purpose of weight management or disease prevention. Decisions about its use should always be made in consultation with a GP or menopause specialist, based on symptoms and individual circumstances.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations, with prescriber review and pharmacist support, where clinically appropriate options may be discussed.

What does the evidence say about diet, exercise, and visceral fat loss?

Clinical evidence consistently supports dietary modification and structured exercise, particularly resistance training, as effective strategies for reducing visceral fat, even without significant total weight loss. UK Chief Medical Officers' guidelines recommend muscle-strengthening activity at least twice weekly alongside 150 minutes of moderate aerobic activity per week.

The evidence consistently supports the view that dietary modification and structured exercise are effective strategies for reducing visceral fat, with resistance training and aerobic exercise both demonstrating benefit in clinical trials. A systematic review and meta-analysis published in Obesity Reviews found that exercise interventions reduced visceral fat even in the absence of significant changes in total body weight, highlighting the importance of looking beyond the scales when assessing metabolic health outcomes.^[5][2]

In terms of diet, research supports reducing intake of refined carbohydrates, added sugars, and ultra-processed foods as part of an overall dietary pattern associated with lower visceral adiposity, though the evidence for ultra-processed food reduction specifically is still developing and should be interpreted alongside broader dietary quality. Higher protein diets have been associated with better preservation of lean muscle mass during caloric restriction, which is relevant for midlife women at risk of sarcopenia.^[14][15] The Mediterranean dietary pattern, which is broadly anti-inflammatory and rich in fibre, healthy fats, and lean protein, has a strong evidence base for cardiovascular and metabolic benefit and aligns closely with the approach Dr Haver advocates.

Resistance training deserves specific mention: evidence from randomised controlled trials indicates that progressive resistance exercise reduces visceral fat and improves insulin sensitivity in postmenopausal women, even when total weight loss is modest.^[5][2] The UK Chief Medical Officers' Physical Activity Guidelines (2019) recommend that adults engage in muscle-strengthening activities on at least two days per week, alongside at least 150 minutes of moderate-intensity aerobic activity (or 75 minutes of vigorous-intensity activity) per week.^[11][12] Sleep quality also has an evidence base: short sleep duration and poor sleep architecture are independently associated with higher visceral fat in population studies, supporting the holistic approach that Dr Haver and other clinicians in this field advocate.

When should you speak to a GP about visceral fat and metabolic health?

Speak to a GP if your waist circumference reaches or exceeds 80 cm as a woman, or if you have risk factors such as a family history of type 2 diabetes or cardiovascular disease. A GP can arrange HbA1c testing, a lipid profile, and referral to relevant NHS services including the Diabetes Prevention Programme.

You should speak to a GP about visceral fat and metabolic health if you have noticed significant changes in your waist circumference, particularly if your waist measurement reaches or exceeds 80 cm (31.5 inches) as a woman (or the relevant threshold for your ethnic background), or if you have risk factors such as a family history of type 2 diabetes, cardiovascular disease, or polycystic ovary syndrome. A GP can arrange relevant investigations to build a picture of your overall metabolic health. In UK primary care, HbA1c is the standard first-line test for assessing blood glucose and diabetes risk: a result of 42 to 47 mmol/mol indicates high risk (sometimes called prediabetes), and 48 mmol/mol or above is diagnostic of type 2 diabetes.^[21] A full lipid profile, liver function tests, and blood pressure measurement may also be arranged.

Women going through perimenopause or menopause who are concerned about changes in body composition, energy levels, or metabolic markers should raise these concerns with their GP, who can discuss whether referral to a menopause clinic or a dietitian would be appropriate. NICE guideline NG23 on menopause provides a framework for the assessment and management of menopausal symptoms, including discussion of HRT where relevant. Your GP can also refer you to the NHS Diabetes Prevention Programme if you are identified as being at high risk of developing type 2 diabetes, or to local weight-management services through your Integrated Care Board (ICB) pathway.

You should contact your GP promptly rather than waiting if you experience:

• Unexplained fatigue, increased thirst, or frequent urination, which may suggest blood glucose dysregulation

• Significant and rapid changes in abdominal girth without obvious dietary cause

• Symptoms of cardiovascular concern such as breathlessness on mild exertion or palpitations

For urgent symptoms such as chest pain or sudden breathlessness, call 999 immediately. For non-emergency health queries outside GP hours, NHS 111 can provide advice. Suspected adverse effects from any medicine can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Engaging with educational content from clinicians such as Dr Haver can be a useful starting point, but it should complement, not replace, a personalised assessment from a UK-registered healthcare professional.

Frequently Asked Questions